Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

FASS Fast and Accurate Solubility for Sustainability

Coordinator
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric), Germany
Runs
1 June 2024 to 30 November 2026
Status
Running
EU funding
€868k
Total cost
€868k
Partners
4 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101159068

What the project is doing

In the project's own words, from its summary on CORDIS.

Solubility measurement is a standard test that is required for every chemical that is produced or tested. However, measuring solubility is a time/labour-intensive process that requires substantial quantities of chemicals. State-of-the-Art solubility measurements are either fast but inaccurate or slow but accurate and require excess of chemicals. FASS is based on high-efficiency second harmonic scattering that combines the analytical advantages of current solubility measurements, fast and accurate, while achieving cutting edge performance in sensitivity and reliability.

FASS saves 90% of cost, 90% of measurement time, 99% of chemicals and 97% of electricity and 80% of compounds compared to the gold standard. As an optical light scattering technique, FASS is non-destructive, and combined with analytical advantages and sustainable use of chemicals and compounds, provides a disruptive innovation in solubility measurement. The consortium is composed of a dedicated startup to bring the instrument to market, a research and technology organization to support technology maturation, a European Research Consortium to enable customer development and instrument demonstration and a center for pharmaceutical research to explore value-added applications of FASS in drug discovery and development.

The goals of the project are: 1) to develop a demonstrator with optimized and robust performance suited for instrument demonstration and application exploration. 2) to validate the technology with early adopters in early stage drug discovery and development and chemical synthesis companies. 3) to develop a feasible business model and go-to-market strategy to be implemented by the startup. FASS brings a sustainable solution to the pharmaceutical and chemical industries, reduce chemical and electrical consumption, and through a dedicated startup, will create jobs, foster competition and contribute to the growth of the pharmaceutical industry and the European economy.

Topics

Who is involved

OrganisationCityCountryRole
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric)BerlinGermanyCoordinator
Fachhochschule Nordwestschweiz FhnwWindischSwitzerlandAssociatedpartner
ORYL Photonics SALausanneSwitzerlandAssociatedpartner
Centre Technologique AlphanovTalenceFranceParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI